Knoll Capital Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Knoll Capital Management’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-10,393	Closed	-$2.25M	–	18
2017 Q1	$2.25M	Hold	10,393	–	–	3.4%	5
2016 Q4	$962K	Sell	10,393 -989	-9%	-$111K	1.69%	12
2016 Q3	$1.5M	Hold	11,382	–	–	2.64%	10
2016 Q2	$1.15M	Hold	11,382	–	–	0.37%	12
2016 Q1	$1.86M	Hold	11,382	–	–	0.76%	9
2015 Q4	$3.73M	Hold	11,382	–	–	1.38%	8
2015 Q3	$3.67M	Hold	11,382	–	–	1.56%	7
2015 Q2	$4.54M	Hold	11,382	–	–	1.46%	8
2015 Q1	$5.6M	Buy	11,382 +2,778	+32%	+$1.08M	1.63%	5
2014 Q4	$3.08M	Hold	8,604	–	–	1.21%	5
2014 Q3	$1.66M	Hold	8,604	–	–	0.65%	7
2014 Q2	$2.06M	Hold	8,604	–	–	0.92%	6
2014 Q1	$2.2M	Hold	8,604	–	–	1.14%	6
2013 Q4	$1.7M	Hold	8,604	–	–	0.86%	7
2013 Q3	$1.45M	Buy	8,604 +3,333	+63%	+$536K	0.78%	7
2013 Q2	$935K	Buy	+5,271	New	+$746K	0.64%	7

Other funds holding LUMO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Knoll Capital Management's LUMO Position: Q2 2017 in Review

Knoll Capital Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2017, closing a stake of 10,393 shares — an estimated $2.25M sold.

Knoll Capital Management first reported a position in LUMO in Q2 2013 and held it in 16 quarters. The position peaked at $5.6M in Q1 2015. 110 funds tracked by Wall St. Rank hold LUMO as of Q2 2017.

Knoll Capital Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
Knoll Capital Management sold 10,393 Lumos Pharma, Inc. Common Stock shares in Q2 2017, an estimated $2.25M.
Knoll Capital Management first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 16 quarters.
Knoll Capital Management's Lumos Pharma, Inc. Common Stock position peaked at $5.6M in Q1 2015.
110 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2017.

Based on Knoll Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.